Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 1;119(8):1624-1627.
doi: 10.14309/ajg.0000000000002796. Epub 2024 Apr 8.

High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort

A Sidney Barritt 4th  1 , Feng Yu  2 , Andrea R Mospan  2 , Phillip N Newsome  3 , Michael Roden  4 , Heather L Morris  2 , Rohit Loomba  5 , Brent A Neuschwander-Tetri  6 ; TARGET-NASH investigators
Affiliations

High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort

A Sidney Barritt 4th et al. Am J Gastroenterol. .

Abstract

Introduction: This study investigates the applicability of the new metabolic dysfunction-associated steatotic liver disease (MASLD) nomenclature to the real-world TARGET-NASH US adult cohort.

Methods: The new MASLD/metabolic steatohepatitis nomenclature was applied to patients enrolled with pragmatic diagnoses of nonalcoholic fatty liver and nonalcoholic steatohepatitis (NASH), and NASH cirrhosis and concordance were determined between the definitions.

Results: Approximately 99% of TARGET-NASH participants met the new MASLD diagnostic criteria. Approximately 1,484/1,541 (96.3%, kappa 0.974) nonalcoholic fatty liver patients (metabolic dysfunction-associated steatotic liver), 2,195/2,201 (99.7%, kappa 0.998) NASH patients (metabolic steatohepatitis), and 1,999/2,003 (99.8%, kappa 0.999) NASH cirrhosis patients met the new criteria.

Discussion: The new MASLD nomenclature is highly concordant with the previous TARGET-NASH pragmatic definitions.

PubMed Disclaimer

References

    1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79(6):1542–56.
    1. Barritt AS, Gitlin N, Klein S, et al. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials 2017;61:33–8.
    1. Barritt AS, Watkins S, Gitlin N, et al. Patient determinants for histologic diagnosis of NAFLD in the real world: A TARGET-NASH study. Hepatol Commun 2021;5(6):938–46.
    1. Kim HP, Idowu MO, Mospan AR, et al. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis. Aliment Pharmacol Ther 2021;54(11–12):1472–80.
    1. Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition? J Hepatol 2024;80(2):e54–6.

Grants and funding